Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis.
Paller AS, de Bruin-Weller M, Marcoux D, Baselga E, Oliveira de Carvalho V, Ardusso LRF, Pasmans SGMA, Toledo-Bahena M, Rubin C, Joyce JC, Wine Lee L, Adams B, Gupta R, Ardeleanu M, Zhang A. Paller AS, et al. Among authors: ardeleanu m. J Am Acad Dermatol. 2025 Feb;92(2):242-251. doi: 10.1016/j.jaad.2024.09.046. Epub 2024 Oct 9. J Am Acad Dermatol. 2025. PMID: 39389429 Free article.
A basophil-neuronal axis promotes itch.
Wang F, Trier AM, Li F, Kim S, Chen Z, Chai JN, Mack MR, Morrison SA, Hamilton JD, Baek J, Yang TB, Ver Heul AM, Xu AZ, Xie Z, Dong X, Kubo M, Hu H, Hsieh CS, Dong X, Liu Q, Margolis DJ, Ardeleanu M, Miller MJ, Kim BS. Wang F, et al. Among authors: ardeleanu m. Cell. 2021 Jan 21;184(2):422-440.e17. doi: 10.1016/j.cell.2020.12.033. Epub 2021 Jan 14. Cell. 2021. PMID: 33450207 Free PMC article.
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, Wu R, Ardeleanu M, Graham NMH, Pirozzi G, Sutherland ER, Mastey V. Simpson EL, et al. Among authors: ardeleanu m. J Am Acad Dermatol. 2016 Sep;75(3):506-515. doi: 10.1016/j.jaad.2016.04.054. Epub 2016 Jun 4. J Am Acad Dermatol. 2016. PMID: 27268421 Clinical Trial.
Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): Baseline characteristics, treatment history and disease burden.
Katoh N, Saeki H, Kataoka Y, Etoh T, Teramukai S, Takagi H, Tajima Y, Ardeleanu M, Rizova E, Arima K; ADDRESS-J Investigators. Katoh N, et al. Among authors: ardeleanu m. J Dermatol. 2019 Apr;46(4):290-300. doi: 10.1111/1346-8138.14787. Epub 2019 Feb 13. J Dermatol. 2019. PMID: 30756423 Free PMC article.
Conjunctivitis in dupilumab clinical trials.
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A. Akinlade B, et al. Among authors: ardeleanu m. Br J Dermatol. 2019 Sep;181(3):459-473. doi: 10.1111/bjd.17869. Epub 2019 May 7. Br J Dermatol. 2019. PMID: 30851191 Free PMC article.
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.
Eichenfield LF, Bieber T, Beck LA, Simpson EL, Thaçi D, de Bruin-Weller M, Deleuran M, Silverberg JI, Ferrandiz C, Fölster-Holst R, Chen Z, Graham NMH, Pirozzi G, Akinlade B, Yancopoulos GD, Ardeleanu M. Eichenfield LF, et al. Among authors: ardeleanu m. Am J Clin Dermatol. 2019 Jun;20(3):443-456. doi: 10.1007/s40257-019-00445-7. Am J Clin Dermatol. 2019. PMID: 31066001 Free PMC article.
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
Cork MJ, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, Girolomoni G, de Bruin-Weller M, Wollenberg A, Kataoka Y, Remitz A, Beissert S, Mastey V, Ardeleanu M, Chen Z, Gadkari A, Chao J. Cork MJ, et al. Among authors: ardeleanu m. J Dermatolog Treat. 2020 Sep;31(6):606-614. doi: 10.1080/09546634.2019.1612836. Epub 2019 Jun 9. J Dermatolog Treat. 2020. PMID: 31179791 Free article. Clinical Trial.
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M. Deleuran M, et al. Among authors: ardeleanu m. J Am Acad Dermatol. 2020 Feb;82(2):377-388. doi: 10.1016/j.jaad.2019.07.074. Epub 2019 Jul 30. J Am Acad Dermatol. 2020. PMID: 31374300 Free article. Clinical Trial.
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q, Shumel B, Khokhar FA, Hultsch T, Rizova E, Rossi AB, Graham NMH, Pirozzi G, Lu Y, Ardeleanu M. Wollenberg A, et al. Among authors: ardeleanu m. Br J Dermatol. 2020 May;182(5):1120-1135. doi: 10.1111/bjd.18434. Epub 2019 Dec 1. Br J Dermatol. 2020. PMID: 31407311 Free PMC article.
71 results